Company profile
The Electrospinning Company | Biomaterials | Regenerative Medicine
The Electrospinning Company Ltd designs, develops and manufactures nanofibrous biomaterials for use in tissue-regenerative devices.
Financial period: 1 Jul 2024 to 30 Jun 2025
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
Last confirmation statement made up date
Last accounts made up date
CS01 | Transaction MzQ0MzcyNjAxMmFkaXF6a2N4
Published 18 Nov 2024 02:36
AP01 | Transaction MzQ0MjY4ODE5OGFkaXF6a2N4
Published 12 Nov 2024 12:49
SH01 | Transaction MzQzNTA3NTM2M2FkaXF6a2N4
Published 10 Sep 2024 10:23
RESOLUTIONS | Transaction WURBVlhNVUJhZGlxemtjeA | Paper/PDF filed
Published 07 Sep 2024 05:59
SH01 | Transaction MzQzNDMyODY0MmFkaXF6a2N4
Published 03 Sep 2024 16:05
Company registered at Companies House
1 Apr 2022 to 31 Dec 2023
This project will progress the development of the Symatix medical device for corneal repair and create a safety data package to obtain approval for first in human clinical trial in the UK. The Symatix device is an innovative, synthetic biomaterial designed to support healing in cornea repair and recalcitrant wounds. It can replace the use of Human Amnioti...
1 Jun 2020 to 28 Feb 2021
no public description
1 Mar 2019 to 30 Jun 2022
For many of us, there is hardly any more life-changing disability imaginable than loss of sight. Whether through trauma or disease, the inability to rely on visual cues impacts on all matters of daily life; doing your job or bringing your kids to school are no longer straightforward activities. Blindness or reduced sight is often caused by a damaged conju...
19 Oct 2018 to 19 Oct 2021
Orthopaedic repair nanofibre scaffold manufacturing scale-up
1 Jan 2018 to 31 Dec 2019
To develop thermoresponsive fibre scaffolds for enzyme-free 3D cell culture.
1 Dec 2015 to 29 Feb 2016
Awaiting Public Project Summary
1 Jun 2015 to 30 Sep 2015
The global market for surgical meshes is over $1 billion and increasing due to increasing obesity and aging populations. Despite being a well-established market there remain unmet needs and attractive opportunities for advanced mesh materials which promote rapid endogenous healing and reduce risk of rejection and infection. In this proposal two SMEs, The ...
1 Sep 2014 to 30 Jun 2016
This project aims to develop novel phenotypic screening systems in which cells are grown in 3D in electrospun polymer microscaffolds in suspension and to evaluate this system with stem cells, recombinant cells and primary cells in a suite of model assays using luminescence, fluorescence and imaging readouts. Adherent cells in 3D could be manipulated as if...
1 Aug 2012 to 31 Jan 2014
The project will develop 96 well microplates with fixed electrospun nanofibre scaffolds for use in 3D cell-based assays. There is strong demand in the pharmaceutical industry for more predictive efficacy and toxicology in vitro assays to reduce both the number of costly drug failures in clinical trials and the number of animals used in pre-clinical testin...
